The refractory response to PD-1/PD-L1 and CTLA4 blockade by immunologically “cold” tumors like CNS, pancreatic, or prostate cancer gave urgency to finding alternatives to these targets that are mainly dependent on an active immune response (48). The gene discussed is CTLA4; the disease is prostate cancer.